Tyr192
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus®
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Tyr192  -  CSDA (human)

Site Information
RRGPPRNyAGEEEEE   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 4780231

In vivo Characterization
Methods used to characterize site in vivo:
mass spectrometry ( 1 , 3 )
Disease tissue studied:
breast cancer ( 1 )
Relevant cell line - cell type - tissue:
HMLER ('stem, breast cancer') ( 1 ) , HMLER ('stem, breast cancer') [CXCR4 (human), knockdown] ( 1 ) , Jurkat (T lymphocyte) ( 3 )

References 

1

Yi T, et al. (2014) Quantitative phosphoproteomic analysis reveals system-wide signaling pathways downstream of SDF-1/CXCR4 in breast cancer stem cells. Proc Natl Acad Sci U S A 111, E2182-90
24782546   Curated Info

2

Schweppe DK, Rigas JR, Gerber SA (2013) Quantitative phosphoproteomic profiling of human non-small cell lung cancer tumors. J Proteomics 91, 286-96
23911959   Curated Info

3

Possemato A (2008) CST Curation Set: 3661; Year: 2008; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS:pSXXXpS
Curated Info